The short answer is that 22C3 is not equivalent to SP142. There are cases that are double-positive but 22C3 positive and SP142 negative cases exist. While benefit from atezolizumab and nab-paclitaxel seems to be seen for SP142 positive breast cancer (based on the results of IMpassion130 trial), the ...